Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brugada syndrome--an update.

Oruganti Sai Satish1, Kuan-Hung Yeh, Ming-Shien Wen

  • 1Nizam's Institute of Medical Sciences, Hyderabad, India.

Chang Gung Medical Journal
|May 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Prognostic value of peak tricuspid regurgitation velocity in hospitalized patients with heart failure with preserved ejection fraction: an multi-institutional study.

Annals of medicine·2026
Same author

Comparative Safety of Advanced Therapies for Crohn Disease.

JAMA network open·2026
Same author

Associations Between the Severity of Sarcopenia and Health-Related Quality of Life in Older Adults.

Journal of clinical medicine·2026
Same author

High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population.

Lipids in health and disease·2025
Same author

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S. Claims-Based Study.

Alimentary pharmacology & therapeutics·2025
Same journal

Leiomyosarcoma of the adrenal vein.

Chang Gung medical journal·2012
Same journal

Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis.

Chang Gung medical journal·2012
Same journal

Team innovation climate and knowledge sharing among healthcare managers: mediating effects of altruistic intentions.

Chang Gung medical journal·2012
Same journal

Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.

Chang Gung medical journal·2012
Same journal

Factors associated with strain in informal caregivers of stroke patients.

Chang Gung medical journal·2012
Same journal

Serum lipid profile could predict the inception and impacts of violent behaviors among acute psychiatric inpatients.

Chang Gung medical journal·2012
See all related articles

Brugada syndrome, a genetic heart condition, is diagnosed via a triad including ECG changes and sudden cardiac death risk. Implantable cardioverter-defibrillator (ICD) therapy is the only proven effective treatment, showing 0% mortality in a 10-year follow-up.

Area of Science:

  • Cardiology
  • Genetics
  • Electrophysiology

Background:

  • Brugada syndrome is characterized by a diagnostic triad: right bundle branch block, ST-segment elevation in V1-V3, and sudden cardiac death (SCD).
  • A familial occurrence in ~50% of patients suggests a genetic basis, with SCN5A gene mutations identified as a cause.
  • Differential diagnosis must exclude other conditions causing precordial ST-segment elevation.

Purpose of the Study:

  • To review the diagnostic criteria and management of Brugada syndrome.
  • To highlight the role of genetic mutations and diagnostic challenges.
  • To discuss current and potential future therapeutic strategies.

Main Methods:

  • Review of diagnostic triad and genetic basis (SCN5A mutations).
  • Discussion of differential diagnoses and provocative drug testing (ajmaline, flecainide, procainamide).

Related Experiment Videos

  • Evaluation of programmed electrical stimulation (PES) for risk stratification and diagnosis.

    • Main Results:

    • Implantable cardioverter-defibrillator (ICD) therapy is the only established effective treatment, with 0% mortality at 10-year follow-up.
    • The accuracy of PES in predicting outcomes, especially in asymptomatic patients, remains debatable.
    • Long-term data for pharmacological therapies (quinidine, isoproterenol) for SCD prevention is incomplete.

    Conclusions:

    • Brugada syndrome requires careful diagnosis, excluding mimics, and genetic testing.
    • ICD implantation is the gold standard for managing high-risk patients.
    • Further research into molecular mechanisms is needed for improved therapeutic strategies.